Structured evidence table for Myo-Inositol Sleep Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Myo-Inositol Sleep Randomized Trial | The global prevalence of PCOS increased from 36.7 to 69.5 million between 1990 and 2021. | 3 | Subakathulla Sumayyah (2026) | Redox-endocrine triad in PCOS: can vitamin D, myo-inositol, and melatonin synergize as bioactive cocktails? |
| Myo-Inositol Sleep Randomized Trial | Emerging evidence underscores that OS is not a mere byproduct of metabolic imbalance but a central driver that disrupts insulin signaling, amplifies androgen biosynthesis, and impairs folliculogenesis (,). | 3 | Subakathulla Sumayyah (2026) | Redox-endocrine triad in PCOS: can vitamin D, myo-inositol, and melatonin synergize as bioactive cocktails? |
| Myo-Inositol Sleep Randomized Trial | Low-dose variants of OCPs have been observed with an increased risk of myocardial infarction and cardiovascular arterial disease (). | 3 | Subakathulla Sumayyah (2026) | Redox-endocrine triad in PCOS: can vitamin D, myo-inositol, and melatonin synergize as bioactive cocktails? |
| Myo-Inositol Sleep Randomized Trial | 1 2 3 4 5 Polycystic ovary syndrome (PCOS) represents one of the most complex endocrine-metabolic disorders affecting women of reproductive age, characterized by a collection of reproductive, metabolic, and psychological manifestations (,). | 3 | Subakathulla Sumayyah (2026) | Redox-endocrine triad in PCOS: can vitamin D, myo-inositol, and melatonin synergize as bioactive cocktails? |
| Myo-Inositol Sleep Randomized Trial | Anxiety and depressive disorders frequently co-occur, and converging evidence from symptom profiles, longitudinal course, shared neurobiological markers, familial aggregation, and treatment response supports a substantial overlap between these conditions []. | 4 | Derkaczew Maria (2026) | Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review |
| Myo-Inositol Sleep Randomized Trial | Importantly, even agents considered comparatively “benign”, such as non-benzodiazepine anxiolytics, may rarely cause significant neurological adverse effects in vulnerable individuals, as illustrated by reports of buspirone-associated dyskinesia or dystonia, plausibly related to its interactions with dopaminergic signaling []. | 4 | Derkaczew Maria (2026) | Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review |
| Myo-Inositol Sleep Randomized Trial | Recent reports have also raised the possibility that selected cyclitols may exert anxiolytic activity; however, robust clinical evidence remains scarce, and the available data are largely preliminary, often derived from indirect observations or preclinical research []. | 4 | Derkaczew Maria (2026) | Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review |
| Myo-Inositol Sleep Randomized Trial | 1 2 3 4 1 Anxiety plays a dual role, encompassing both adaptive and maladaptive dimensions. | 4 | Derkaczew Maria (2026) | Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review |
Source documents